Developing drug substances using AI-driven computational solutions with increased efficacy and reduced side effects
21 Nov 2024
Lead Generation & Optimization
- How can the use of AI leverage the further improvement of design and selection of drug substances?
- What challenges, especially with the broader design space, does the domain have which others, e.g. small-molecule or peptide-derived domains, don’t have or even already have solved?
- Which way can we integrate, the most crucial piece of data, human derived responses, into the development of better AI models and drug substances.
- Is there a need for a standard validation data package provided by regulators to accelerate the development of AI based drug design solutions? If so, how could this look like?
Industry Expert
